HGFL α inhibitors belong to a distinct chemical class characterized by their ability to selectively modulate the activity of the hepatocyte growth factor-like (HGFL) α protein. These inhibitors are designed to interact with specific binding sites on the HGFL α protein, effectively obstructing or altering its normal biochemical functions. The chemical structure of HGFL α inhibitors is engineered to achieve a high degree of affinity and specificity for the target protein, thereby regulating its signaling pathways or physiological responses. Through their intricate molecular interactions, these inhibitors play a pivotal role in influencing cellular processes where HGFL α is involved.
The development of HGFL α inhibitors involves meticulous design and optimization to ensure optimal binding and efficacy. Researchers in this field explore the structural intricacies of both the inhibitors and the HGFL α protein to fine-tune the interaction between the two entities. This chemical class represents a sophisticated approach to manipulating cellular functions associated with HGFL α, with applications in various contexts where precise modulation of this protein's activity is desired.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
A multi-kinase inhibitor that targets c-MET, vascular endothelial growth factor receptor (VEGFR), and rearranged during transfection (RET) kinases, among others. | ||||||
ARQ 197 | 905854-02-6 | sc-364408 sc-364408A | 50 mg 200 mg | $712.00 $1920.00 | ||
Originally developed as a c-MET inhibitor, Tivantinib was investigated for its potential in inhibiting HGF signaling and metastasis. | ||||||
Foretinib | 849217-64-7 | sc-364492 | 5 mg | $129.00 | 6 | |
An investigational c-MET and VEGFR kinase inhibitor studied in research models for various cancers. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
While primarily known as a VEGFR inhibitor, Lenvatinib has also shown some inhibitory activity against c-MET. | ||||||
Met Kinase Inhibitor | 658084-23-2 | sc-204801 | 1 mg | $116.00 | 5 | |
Another c-MET inhibitor that has demonstrated inhibitory effects on HGF-induced c-MET activation. | ||||||